FDA Watch: User Fees Dodge a Bullet, a Cancer Drug Approval Breaks New Ground and the Supreme Court Serves Up a Biosims Blockbuster

摘要

The FDA budget pot continues to boil. In March, the Trump administration proposed a controversial provision to double the medical user fees that diagnostics, medical device and pharma companies pay to have the FDA review their products. "Industries that directly benefit from FDA's medical product premarket approval ... can and should pay more to support FDA's continued capacity," the administration argued.